Intense competition in ADCs means Pheon is holding back details on its technology as it heads into Phase I studies after a $120m series B fundraising.

Emerging Company Profile: Efficacy data on the young group’s first pH-engineered antibody-drug conjugate could come next year, and potential partners will be watching.

The UK company has unveiled a new strategy for 2030 and beyond but analysts' forecasts fall around $15bn short of the company’s own projections.

Glenmark to progress BeiGene’s key assets in India, a market where rival PD-1 inhibitors and BTK inhibitors have a head start. All eyes are on the regulatory pathway, which provides for a waiver of local trial requirements for new drugs on a case-by-case basis, subject to certain criteria.